RECRUITING

Mechanisms of Resistance to PSMA Radioligand Therapy

Talk to us

Conditions

Prostate CancerRadioligand Therapy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.

Official Title

Mechanisms of Resistance to PSMA Radioligand Therapy: Radiation Resistance Versus Dose

Quick Facts

Study Start:2021-10-21
Study Completion:2024-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05435495

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Initiating treatment with Lutetium based PSMA-targeted RLT.
  2. 2. Participants must have a PSMA-avid lesion that is accessible to biopsy. Biopsy of newly emerging radiographic metastases is desired and preferable to the biopsy of previously existing lesions whenever possible. Newly emerging lesions are defined as those that are absent on a previous scan, or those demonstrating unequivocal progression since initiation of the last treatment. Biopsies will be performed according to local institutional standards.
  3. 3. Patients on warfarin, aspirin, or other anti-coagulants are eligible provided they are deemed able to tolerate discontinuation of anti-coagulation for at least five days prior to the biopsy. Conversion to low molecular weight heparin prior to biopsy is permitted per local standard operating procedures, provided there is approval by the interventional radiologist or the PI.
  4. 4. Age \>=18 years.
  5. 5. Ability to understand and the willingness to sign a written informed consent document.
  1. 1. Patients with significant congenital or acquired bleeding disorders (eg von Wildebrand's disease, acquired bleeding factor inhibitors).
  2. 2. Patients who are not able to undergo additional study related imaging procedures.

Contacts and Locations

Study Contact

Maya Aslam
CONTACT
(415) 514-8987
Maya.Aslam@ucsf.edu

Principal Investigator

Thomas Hope, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, Los Angeles
Los Angeles, California, 90095
United States
University of California, San Francisco
San Francisco, California, 94143
United States
Memorial Sloan Kettering
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Thomas Hope, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-10-21
Study Completion Date2024-12-31

Study Record Updates

Study Start Date2021-10-21
Study Completion Date2024-12-31

Terms related to this study

Keywords Provided by Researchers

  • Radioligand Therapy

Additional Relevant MeSH Terms

  • Prostate Cancer